NYSE:JNJ - Johnson & Johnson Stock Price, News, & Analysis

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Johnson & Johnson announced a quarterly dividend on Wednesday, January 2nd. Shareholders of record on Tuesday, February 26th will be paid a dividend of $0.90 per share on Tuesday, March 12th. This represents a $3.60 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Monday, February 25th. View Johnson & Johnson's Dividend History.

Johnson & Johnson declared that its Board of Directors has authorized a stock repurchase plan on Monday, December 17th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 1.5% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board believes its shares are undervalued.

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday, April, 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.83 EPS. View Johnson & Johnson's Earnings History.

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Johnson & Johnson.

Johnson & Johnson will be holding an earnings conference call on Tuesday, January 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Johnson & Johnson issued an update on its FY18 earnings guidance on Monday, December, 17th. The company provided EPS guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.16. The company issued revenue guidance of $81.0-81.4 billion, compared to the consensus revenue estimate of $81.39 billion.Johnson & Johnson also updated its FY 2018 guidance to $8.13-8.18 EPS.

13 brokerages have issued twelve-month price objectives for Johnson & Johnson's stock. Their forecasts range from $110.00 to $160.00. On average, they expect Johnson & Johnson's share price to reach $139.5455 in the next year. This suggests a possible upside of 8.5% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Johnson & Johnson.

News stories about JNJ stock have trended positive recently, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Johnson & Johnson earned a news impact score of 2.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next few days.

Johnson & Johnson saw a drop in short interest in December. As of December 31st, there was short interest totalling 15,719,662 shares, a drop of 19.9% from the December 14th total of 19,633,883 shares. Based on an average daily trading volume, of 15,979,892 shares, the short-interest ratio is currently 1.0 days. Currently, 0.6% of the shares of the company are short sold. View Johnson & Johnson's Current Options Chain.

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).

Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.06%), Hexavest Inc. (0.06%), Gateway Investment Advisers LLC (0.05%), Confluence Investment Management LLC (0.04%), Cornerstone Investment Partners LLC (0.03%) and KAMES CAPITAL plc (0.03%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

JNJ stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Atalanta Sosnoff Capital LLC, Sit Investment Associates Inc., USS Investment Management Ltd, Highland Capital Management LLC, Hexavest Inc., Moreno Evelyn V and Chickasaw Capital Management LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

JNJ stock was acquired by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, DNB Asset Management AS, Ferguson Wellman Capital Management Inc., QCI Asset Management Inc. NY, Centre Asset Management LLC, Steward Partners Investment Advisory LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO and Hotaling Investment Management LLC. View Insider Buying and Selling for Johnson & Johnson.

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNJ stock can currently be purchased for approximately $128.6650.

Johnson & Johnson has a market capitalization of $347.06 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

The official website for Johnson & Johnson is http://www.jnj.com.

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.